The North America Allergy Diagnostics Market is witnessing robust growth, driven by increasing prevalence of allergic disorders and technological advancements in diagnostic solutions. The market was valued at USD 2,300 Million in 2025 and is expected to reach USD 5,600 Million by 2035, growing at a CAGR of 8.6% from 2024 to 2035.
The economic impact of tariffs on "North America Allergy Diagnostics Market".
Market Growth Drivers
Rising Prevalence of Allergies: The increasing incidence of respiratory, food, and drug allergies in North America is fueling demand for advanced diagnostic solutions. According to Thermo Fisher Scientific, the number of individuals with allergic rhinitis and food allergies has continued to rise, especially among pediatric and adult populations, resulting in higher demand for allergy testing kits and systems across healthcare facilities.
Advancements in Allergy Diagnostic Technologies: The rapid development of innovative diagnostic platforms, such as multiplex allergy testing and point-of-care solutions by companies like bioMérieux, is enabling faster and more accurate detection. These advancements are reducing time to results and improving patient care outcomes, thereby propelling the adoption of allergy diagnostic products.
Market Trends
Integration of Artificial Intelligence: Leading companies such as Siemens Healthineers are leveraging AI algorithms to interpret complex allergy data, enabling more precise diagnoses and personalized treatment plans. AI-based platforms streamline workflows for clinicians and enhance the detection accuracy of allergy diagnostics.
Home-Based Allergy Testing Kits: Companies like Quest Diagnostics are expanding their offering of at-home allergy testing kits, allowing consumers to collect samples conveniently and safely without visiting clinics. This trend surged post-pandemic and is expected to accelerate, aiding market penetration in remote and underserved areas.
Market Opportunities
Expansion in Pediatric Allergy Diagnostics: With a growing prevalence of allergies among children, companies like Thermo Fisher Scientific can expand specialized panels and non-invasive diagnostics tailored for pediatric populations, opening new revenue streams.
Collaborations with Digital Health Platforms: Strategic alliances between diagnostic firms and telehealth providers present opportunities for integrated allergy management services, improving accessibility and offering comprehensive remote consultations.
North America Allergy Diagnostics Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates a steady uptrend in the North America Allergy Diagnostics Market from 2020 to 2035. Starting at USD 1,210 million in 2020, the market demonstrates consistent year-on-year growth, propelled by rising allergy prevalence and new diagnostic technologies. By 2025, revenues are projected at USD 2,300 million, accelerating further to exceed USD 5,600 million by 2035, marking a significant CAGR of 8.6%. This expansion signifies robust industry optimism, with hospitals, clinics, and at-home diagnostics driving long-term growth. Notably, acceleration from 2028 onwards underscores the impact of next-gen diagnostics and digital health integrations.
North America Allergy Diagnostics Market by Region, 2025
In 2025, the United States dominates the North America Allergy Diagnostics Market, holding a market share of 74%. This is attributed to the large patient pool, advanced healthcare infrastructure, and leading diagnostic players. Canada follows with a 17% share, supported by increased healthcare spending on allergy detection. Mexico holds a 5% share due to rising urbanization and awareness, while the rest of North America, including the Caribbean, represent 4% collectively. Regional diversification highlights the need for targeted market strategies and expansion by diagnostics companies.
Recent Developments in North America Allergy Diagnostics Market
In February 2024, Thermo Fisher Scientific launched the ImmunoCAP Specific IgE 2.0 system, introducing a next-generation diagnostic platform that significantly accelerates allergy test turnaround times and expands the range of allergens detectable in a single test. The system utilizes improved reagent sensitivity, allowing healthcare providers to enhance diagnostic accuracy for complex cases.
In March 2024, Siemens Healthineers announced a strategic collaboration with Teladoc Health to develop integrated digital diagnostic capabilities for allergies. This partnership aims to combine Siemens' allergy diagnostic instruments with Teladoc's telemedicine infrastructure, offering seamless remote consultations and allergy management solutions for patients across North America.
In May 2024, Quest Diagnostics expanded its consumer health division by acquiring the North American assets of a leading at-home allergy testing startup. This move strengthens Quest’s direct-to-consumer market reach, offering a range of convenient allergy test kits complete with digital reporting and remote physician follow-ups, in response to the growing trend for home-based diagnostics.
Press Releases